ArticleACG case reports journal2025
Rapid Resolution of Perianal Crohn's Disease with Upadacitinib.
Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Explainable random forest-SHAP framework for Montreal phenotype-stratified prediction of one-year complications in Crohn's disease.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 20-year-old woman with ileocolonic, stricturing, and penetrating Crohn's disease (CD) presented with new onset perianal and vulvar CD despite having a diverting ileostomy and medical therapy with ustekinumab. She had previous secondary nonresponse to infliximab, vedolizumab, and adalimumab. There is a paucity of data supporting the use of medical therapies for perianal CD. Upadacitinib is approved for treatment of moderate to severely active ulcerative colitis and CD. This case demonstrates successful and rapid resolution of perianal CD within weeks of initiating upadacitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.